Radioimmunotherapy in the treatment of malignant astrocytomas

Jacqueline G. Emrich, John R Vender

Research output: Contribution to journalReview article

Abstract

The poor prognosis of patients diagnosed with malignant astrocytomas and the failure of conventional therapies to significantly impact the course of this disease have resulted in the development of a number of experimental adjuvant therapies, including radioimmunotherapy (RIT). Certain human gliomas have been associated with an overexpression of the epidermal growth factor receptor (EGFR). Radiolabeled antibodies that target these receptors and are quickly internalized can effectively deliver ionizing radiation to ensure tumor cell kill, particularly to residual tumor masses unaffected by standard treatment regimens. The fundamental components integrated for this evolving adjuvant therapy are detailed and key current experimental studies using RIT are described. Evaluation of the current radioimmunotherapeutic results indicates that certain radiolabeled MAbs have a role in the diagnosis and/or treatment of malignant gliomas.

Original languageEnglish (US)
Pages (from-to)87-92
Number of pages6
JournalDrug Delivery: Journal of Delivery and Targeting of Therapeutic Agents
Volume3
Issue number2
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Radioimmunotherapy
Astrocytoma
Glioma
Investigational Therapies
Residual Neoplasm
Therapeutics
Ionizing Radiation
Epidermal Growth Factor Receptor
Antibodies
Neoplasms

Keywords

  • Anaplastic astrocytoma
  • Epidermal growth factor receptor
  • Glioblastoma multiforme
  • Radioimmunotherapy
  • Radiolabeled antibodies

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Radioimmunotherapy in the treatment of malignant astrocytomas. / Emrich, Jacqueline G.; Vender, John R.

In: Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents, Vol. 3, No. 2, 01.01.1996, p. 87-92.

Research output: Contribution to journalReview article

@article{561917ce7f0c4a63b924e4a9c64c0374,
title = "Radioimmunotherapy in the treatment of malignant astrocytomas",
abstract = "The poor prognosis of patients diagnosed with malignant astrocytomas and the failure of conventional therapies to significantly impact the course of this disease have resulted in the development of a number of experimental adjuvant therapies, including radioimmunotherapy (RIT). Certain human gliomas have been associated with an overexpression of the epidermal growth factor receptor (EGFR). Radiolabeled antibodies that target these receptors and are quickly internalized can effectively deliver ionizing radiation to ensure tumor cell kill, particularly to residual tumor masses unaffected by standard treatment regimens. The fundamental components integrated for this evolving adjuvant therapy are detailed and key current experimental studies using RIT are described. Evaluation of the current radioimmunotherapeutic results indicates that certain radiolabeled MAbs have a role in the diagnosis and/or treatment of malignant gliomas.",
keywords = "Anaplastic astrocytoma, Epidermal growth factor receptor, Glioblastoma multiforme, Radioimmunotherapy, Radiolabeled antibodies",
author = "Emrich, {Jacqueline G.} and Vender, {John R}",
year = "1996",
month = "1",
day = "1",
doi = "10.3109/10717549609031178",
language = "English (US)",
volume = "3",
pages = "87--92",
journal = "Drug Delivery",
issn = "1071-7544",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Radioimmunotherapy in the treatment of malignant astrocytomas

AU - Emrich, Jacqueline G.

AU - Vender, John R

PY - 1996/1/1

Y1 - 1996/1/1

N2 - The poor prognosis of patients diagnosed with malignant astrocytomas and the failure of conventional therapies to significantly impact the course of this disease have resulted in the development of a number of experimental adjuvant therapies, including radioimmunotherapy (RIT). Certain human gliomas have been associated with an overexpression of the epidermal growth factor receptor (EGFR). Radiolabeled antibodies that target these receptors and are quickly internalized can effectively deliver ionizing radiation to ensure tumor cell kill, particularly to residual tumor masses unaffected by standard treatment regimens. The fundamental components integrated for this evolving adjuvant therapy are detailed and key current experimental studies using RIT are described. Evaluation of the current radioimmunotherapeutic results indicates that certain radiolabeled MAbs have a role in the diagnosis and/or treatment of malignant gliomas.

AB - The poor prognosis of patients diagnosed with malignant astrocytomas and the failure of conventional therapies to significantly impact the course of this disease have resulted in the development of a number of experimental adjuvant therapies, including radioimmunotherapy (RIT). Certain human gliomas have been associated with an overexpression of the epidermal growth factor receptor (EGFR). Radiolabeled antibodies that target these receptors and are quickly internalized can effectively deliver ionizing radiation to ensure tumor cell kill, particularly to residual tumor masses unaffected by standard treatment regimens. The fundamental components integrated for this evolving adjuvant therapy are detailed and key current experimental studies using RIT are described. Evaluation of the current radioimmunotherapeutic results indicates that certain radiolabeled MAbs have a role in the diagnosis and/or treatment of malignant gliomas.

KW - Anaplastic astrocytoma

KW - Epidermal growth factor receptor

KW - Glioblastoma multiforme

KW - Radioimmunotherapy

KW - Radiolabeled antibodies

UR - http://www.scopus.com/inward/record.url?scp=0029785173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029785173&partnerID=8YFLogxK

U2 - 10.3109/10717549609031178

DO - 10.3109/10717549609031178

M3 - Review article

AN - SCOPUS:0029785173

VL - 3

SP - 87

EP - 92

JO - Drug Delivery

JF - Drug Delivery

SN - 1071-7544

IS - 2

ER -